New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

"I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team,” stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance.

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

GOMEKLI™ is an oral, small molecule MEK inhibitor approved in the United States for the treatment of adult and pediatric ...

European Union lawmakers designed EU Clinical Trial Regulation 536/2014 to heighten interest within the healthcare industry for planning and conducting clinical trials in the EU, which experienced ...

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol) ...